Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charting the Course: From Young Adult Leukemia Patient to Oncologist.

2.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

3.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

4.

Researchers explore e-bikes for cancer recovery

5.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot